Literature DB >> 30219625

Encorafenib plus binimetinib: an embarrassment of riches.

Juan Martin-Liberal1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30219625     DOI： 10.1016/S1470-2045(18)30530-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  BRAF mutation and its inhibitors in sarcoma treatment.

Authors:  Haotian Liu; Nahar Nazmun; Shafat Hassan; Xinyue Liu; Jilong Yang
Journal:  Cancer Med       Date:  2020-05-31       Impact factor: 4.452

2.  Defining subpopulations of differential drug response to reveal novel target populations.

Authors:  Nirmal Keshava; Tzen S Toh; Haobin Yuan; Bingxun Yang; Michael P Menden; Dennis Wang
Journal:  NPJ Syst Biol Appl       Date:  2019-10-03

3.  V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients.

Authors:  Aihemaijiang Kuerbanjiang; Maimaitiyiming Maimaituerxun; Yanjun Zhang; Yiliang Li; Gang Cui; Aibaidula Abuduhabaier; Abuduwaili Aierken; Buya Miranbieke; Meilikezati Anzaer; Yusufu Maimaiti
Journal:  BMC Gastroenterol       Date:  2021-02-23       Impact factor: 3.067
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.